232 filings
Page 2 of 12
8-K
1fz20zc9dmml
27 May 22
Regulation FD Disclosure
8:44am
8-K
egp4xzfwres8wjsomkl
12 Jan 22
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
10:08am
8-K
vk3b1s
10 Jan 22
Regulation FD Disclosure
6:02am
8-K
92ab1sa
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
i6499wdidw7hx zx
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
s3ln mg85mfw1g2iehss
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
tp3pfoysa8a1 loi
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
dlajzsxawi4
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
xrq5jpxyt
8 Oct 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
8hqkjn o3dvwtg6g86
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
silhaj8fkipj jz66
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
b3kmno6d igy7i
29 Sep 21
Other Events
9:22am
8-K
aomw0c8
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
qut 5h20yr2s
23 Aug 21
Amendments to Articles of Incorporation or Bylaws
9:19am
8-K
tena23g 1y8
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
20j y4azm8
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
8-K
6d57awc5
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
c7q8l
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am
8-K
4gzojc4ji9
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
mmu57avdsfz5hen
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am